![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Finn, Richard S.; Yau, Thomas; Hsu, Chih-Hung; De Toni, Enrico N.; Goyal, Lipika; Galle, Peter R.; Qin, ShuKui; Rao, Sujata; Sun, Fangfang; Wang, Chunxiao; Widau, Ryan C. und Zhu, Andrew X.
(2022):
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
In: Oncologist, Bd. 27, Nr. 12, E938-E948
2020
de Bono, Johann; Lin, Chia-Chi; Chen, Li-Tzong; Corral, Jesus; Michalarea, Vasiliki; Rihawi, Karim; Ong, Michael; Lee, Jih-Hsiang; Hsu, Chih-Hung; Yang, James Chih-Hsin; Shiah, Her-Shyong; Yen, Chia-Jui; Anthoney, Alan; Jove, Maria; Buschke, Susanne; Fuertig, Rene; Schmid, Ulrike; Goeldner, Rainer-Georg; Strelkowa, Natalja; Huang, Dennis Chin-Lun; Bogenrieder, Thomas; Twelves, Chris und Cheng, Ann-Lii
(2020):
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
In: British Journal of Cancer, Bd. 122, Nr. 9: S. 1324-1332